Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases
https://t.co/gm76Pzw0KT

In memoriam Nicola Bidoli

VLP applications characteristics challenges
VLP Induction of innate and adaptive immunological responses (A) humoral immunity; (B) cell-mediated immunity) by VLPs
VLPs Advantages and limitations of different expression systems for the development of virus-like particles.
VLP vaccines against different viruses and parasites.
VLP - how to produce them
Proposed production system and mechanism of action of SARS-CoV2 virus-like particle vaccine. Plasmids encoding the structural proteins (S, N, M, and E) of the SARS-CoV2 can be transfected into an appropriate mammalian cell line.

More from rubic3n

Fondation Merieux
2017
Pushing the
CEPI Dialogue

Excellent presentation to see, how they, including Bancel, had layed out the narrative.
Quess, what they had specifically included in their list of targeted viruses?

https://t.co/J5FDe6W986


Fondation Merieux 2017
CEPI
Almost basking about their list being more inclusive, more emergent viruses based.
https://t.co/J5FDe6W986


Fondation Merieux 2017
Narrative: "Look, what ZIKA has done to your populace. Nasty ZIKA."

How much of that ZIKA damage was actually related to a virus? Was there a computer guy, who had invested in mosquitos as a vector?

https://t.co/J5FDe6W986


Fondation Merieux 2017
What is the advanges of a programme like CEPI.

And for who?

Let me translate: They want a coordinated vaccine production, with only one strong production pipeline, and solidly regulated pathsways.
Provide the incentives for big pharma.

They've made it.


Vision - look at nasty ZIKA, you surely do not want that
Mission - get the pipeline going of (only) the big ones
Scope - the anti-cancer platforms with their DNA, mRNA basis fit perfectly. They so far do not sell very well, but they could be recycled.

Correct me, if I am wrong.
80% of diseases not treatable with 'conventional medicine'. Protein treatment as an alternative with drawbacks.
An 80% market for mRNA. Yet, the vector is the bottleneck causing the limitation.
Viral V is almost a 'use once only' bcs of antibody formation.
LNP sole way to push.


mRNA Therapy - with a gargantuan market - in dire need for a vector.
Viral vectors as a dead ally until 2015.
mRNA Therapy meets enormous resentments.

Luckily, billions of people have now got first hand experience. Obviously, AZ was not that useful in the general drift.


LNP instead of a vector
PFIZER BioNtech

ALC-0315
ALC-0159, DSPC
"This product is for research use only and not for human use."
https://t.co/tNsG5wxVCT

'EMA Zulassung ohne


Official statement by Echelon
Paraphrased - "we do produce it, but only for use in labs.
Pfizer get theirs from other companies. With them it is safe in humans."

No study data presented
A reference to GMP as 'safe in humans'

ALC-0315
ALC-0159, DSPC


PFIZER LNP

This paper claims "It is just like another fatty compound. You eat salad oil and chips as well"

https://t.co/uncdUpkFnI

No, it is not.
@Keane1975 Die Forschung mit Virenmanipulation und mRNA Impfstoffen geht dem schon seitlich weit voraus.
Nachfolgend
- zum Bau des Labors in Wuhan durch BioMerieux -> Bancel jetzt Moderna
- Werbebroschüre BioMerieux (CEPI GAVI Einbindung)
- Moderna ominöser geheimer weiterer Impfstoff
1

Bau des Labors in Wuhan BioMerieux Beteiligung
2004


Bancel BioMerieux


Mehr zum Bau des Labors durch BioMerieus in Wuhan (Stephane Bancel ex BioMerieux jetzt


Bancel BioMerieux Wuhan

You May Also Like

@franciscodeasis https://t.co/OuQaBRFPu7
Unfortunately the "This work includes the identification of viral sequences in bat samples, and has resulted in the isolation of three bat SARS-related coronaviruses that are now used as reagents to test therapeutics and vaccines." were BEFORE the


chimeric infectious clone grants were there.https://t.co/DAArwFkz6v is in 2017, Rs4231.
https://t.co/UgXygDjYbW is in 2016, RsSHC014 and RsWIV16.
https://t.co/krO69CsJ94 is in 2013, RsWIV1. notice that this is before the beginning of the project

starting in 2016. Also remember that they told about only 3 isolates/live viruses. RsSHC014 is a live infectious clone that is just as alive as those other "Isolates".

P.D. somehow is able to use funds that he have yet recieved yet, and send results and sequences from late 2019 back in time into 2015,2013 and 2016!

https://t.co/4wC7k1Lh54 Ref 3: Why ALL your pangolin samples were PCR negative? to avoid deep sequencing and accidentally reveal Paguma Larvata and Oryctolagus Cuniculus?
So the cryptocurrency industry has basically two products, one which is relatively benign and doesn't have product market fit, and one which is malignant and does. The industry has a weird superposition of understanding this fact and (strategically?) not understanding it.


The benign product is sovereign programmable money, which is historically a niche interest of folks with a relatively clustered set of beliefs about the state, the literary merit of Snow Crash, and the utility of gold to the modern economy.

This product has narrow appeal and, accordingly, is worth about as much as everything else on a 486 sitting in someone's basement is worth.

The other product is investment scams, which have approximately the best product market fit of anything produced by humans. In no age, in no country, in no city, at no level of sophistication do people consistently say "Actually I would prefer not to get money for nothing."

This product needs the exchanges like they need oxygen, because the value of it is directly tied to having payment rails to move real currency into the ecosystem and some jurisdictional and regulatory legerdemain to stay one step ahead of the banhammer.